New hope for kids with ITP: drug combo aims to control bleeding
NCT ID NCT07660172
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding ianalumab to eltrombopag helps children aged 5 to 17 with primary immune thrombocytopenia (ITP) who didn't improve after steroids. The goal is to see if the combination can raise platelet counts and prevent bleeding. About 36 children will take part, and the study is not yet open for enrollment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ianalumab (a biologic drug) plus eltrombopag (a pill or liquid to raise platelet counts)
- What this could lead to
- If it works, this combination could offer a new treatment option for children with ITP who don't respond to steroids, helping control bleeding risk.
- What could go wrong
- This is a small, early-phase trial with only 36 children, so results may not apply to all. The drugs may cause side effects like infections or liver issues, and the study is not yet recruiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill could help adults with low platelet disorder
- New drug combo aims to boost platelet counts in immune disorder
- New combo aims to boost platelets in stubborn ITP
- New hope for ITP patients: switching drugs after failed treatment
- New shot aims to boost platelets in ITP patients
- New combo therapy aims to tame rare bleeding disorder